

Ref: EPL/CS/SE/0051/2025**Date:** June 25, 2025

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Regulatory Order(s)

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we hereby submit the disclosure regarding the Order received in the matter of application under Section 441 of the Companies Act, 2013 ("the Act"), in the matter of compounding of offence under Section 152 of the Act, from the Office of the Regional Director, Western Region, Ministry of Corporate Affairs, Mumbai, on June 24, 2025.

The relevant details as required pursuant to Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are provided in "**Annexure A**", enclosed herewith.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

Chetan Sharma
Company Secretary & Compliance Officer
Membership Number: F8352

Emcure Pharmaceuticals Limited**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India**Phone Nos.:** +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

Annexure-A

Disclosure under Para A of Part A of Schedule III to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sr. No.	Particulars	Information
1	Name of the Authority	Regional Director, Western Region, Ministry of Corporate Affairs, Mumbai
2	Nature and details of the action(s) taken, initiated or order(s) passed	Vide the Order, the Regional Director, exercising the powers under Section 441 of the Companies Act, 2013 ("the Act"), has compounded the alleged violation of Section 152 of the Act and imposed a total compounding fees of Rs. 1,75,000/- (i.e., Rs. 87,500/- each for two (2) applicant Directors, including one ex-Director). The directors have paid the aggregate compounding fees from their own funds, and the compounding application stands disposed-off.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	June 24, 2025
4	Details of the violation(s)/contravention(s) committed or alleged to be committed	During the Annual General Meetings ("AGMs") held on July 27, 2015, and August 03, 2016, although two (2) directors were due to retire by rotation each year, only one (1) director was retired in the AGMs of 2015 and 2016. The alleged violation of Section 152 of the Act, now stands compounded.
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible.	There is no material impact in the Company's financials, operations or other activities, due to the said Order.

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 - 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251